Shares in Sanofi were sliding today after a double dose of bad news for its oral BTK inhibitor tolebrutinib, in development as a therapy for multiple sclerosis (MS). Along with what looks set to be ...
Sanofi went into the Christmas break with news of a takeover deal to boost its vaccines business, even as the FDA sent an early complete response letter for its oral multiple sclerosis candidate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results